{"cluster": 36, "subcluster": 51, "abstract_summ": "Multisensors, lateral flow tests, mobile biosensors, and wearable biosensors are seen as key players for precision medicine in COVID-19.At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses.Here, a potential radiation-mediated CS regulation is raised by reevaluating the radiation-mediated pneumonia control in the 1920s with the following latent advantages of lung radiotherapy (LR) in treatment of COVID-19: a, Radiation accesses poorly-circulated tissue more efficiently than blood-delivered medications; b, Low dose radiation (LDR)-mediated metabolic rewiring and immune cell activation inhibit virus loading; c, Pre-consumption of immune reserves by LDR decreases CS severity; d, High dose radiation (HDR) within lung-tolerable doses relieves CS by eliminating in situ overactive cytokine-releasing cells.Facing Severe Acute Respiratory Syndrome Coronavirus\u20102 (SARS\u2010CoV\u20102), we simply do not have the time to develop the vaccine before thousands of people die.The mammalian target of rapamycin (mTOR) inhibitors satisfy such needs and it is recommended to conduct clinical trials for mTOR inhibitors in preventing the severity of COVID\u201019.Summary The acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2 mediated cytokine storm (CS) in lungs leads the high mortality in COVID-19 patients.This manuscript reviews the different aspects of blood purification in critically ill patients with AKI and increased inflammatory factors, and examines its potential role in severe COVID-19 treatment.", "title_summ": "Is Inhaled Furosemide a Potential Therapeutic for COVID-19?Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?Immunoregulation with mTOR inhibitors to prevent COVID\u201019 severity: A novel intervention strategy beyond vaccines and specific antiviral medicinesMitigating coronavirus-induced acute respiratory distress syndrome by radiotherapyNoscapine, a possible drug candidate for attenuation of cytokine release associated with SARS\u2010CoV\u20102Biosensors for Managing the COVID-19 Cytokine Storm: Challenges AheadPulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19", "title_abstract_phrases": "Multisensors, lateral flow tests, mobile biosensors, and wearable biosensors are seen as key players for precision medicine in COVID-19.Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses.Here, a potential radiation-mediated CS regulation is raised by reevaluating the radiation-mediated pneumonia control in the 1920s with the following latent advantages of lung radiotherapy (LR) in treatment of COVID-19: a, Radiation accesses poorly-circulated tissue more efficiently than blood-delivered medications; b, Low dose radiation (LDR)-mediated metabolic rewiring and immune cell activation inhibit virus loading; c, Pre-consumption of immune reserves by LDR decreases CS severity; d, High dose radiation (HDR) within lung-tolerable doses relieves CS by eliminating in situ overactive cytokine-releasing cells.The mammalian target of rapamycin (mTOR) inhibitors satisfy such needs and it is recommended to conduct clinical trials for mTOR inhibitors in preventing the severity of COVID\u201019.Mitigating coronavirus-induced acute respiratory distress syndrome by radiotherapySummary The acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2 mediated cytokine storm (CS) in lungs leads the high mortality in COVID-19 patients.Facing Severe Acute Respiratory Syndrome Coronavirus\u20102 (SARS\u2010CoV\u20102), we simply do not have the time to develop the vaccine before thousands of people die.Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?The coronavirus disease-19 (COVID-19) has spread over many countries and regions since the end of 2019, becoming the most severe public health event at present."}